Purchase ACPE Credit for this activity ($22.50) ►
	Purchase ACPE Credit at the SIDP Member Rate ($15) ► Login to SIDP to verify your membership, then follow the members only link to receive the discount.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)

 
 View more SIDPEC Activities ►
 

Activity Description

Beta-lactam, sulfa, and fluoroquinolone allergies are the most commonly reported antibiotic allergies. There are conflicting practice habits about the safety of using antibiotics within the same class as the primary allergen. This results in the avoidance of all first line medications for patients labeled as penicillin, sulfa, or fluoroquinolone allergic. This webinar will use five clinical scenarios to explore treatment options for patients with antibiotic allergies. The cases will focus on use of sulfonamide nonantibiotics in patients with sulfa antibiotic allergies, use of ceftriaxone and cefazolin in patients with penicillin allergies, oral amoxicillin/penicillin challenge for patients with penicillin allergies, and fluoroquinolone cross-reactivity.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:

• Discuss physiology of hypersensitivity reactions.
• Identify the mechanisms of cross-reactivity between and among sulfa containing medications, beta-lactams, and fluoroquinolones.
• Interpret the available clinical evidence measuring risk of hypersensitivity.
• Explain how to create antimicrobial regimens for patients with antimicrobial allergies.

Faculty

Meghan Jeffres, PharmD, BCIDP
Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy

CE Accreditation

Pharmacists

Release Date: 6-27-2019
Expiration Date: 6-27-2022

This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-225-H01-P has been assigned to this home study knowledge-based activity (initial release date 6-27-2019). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

BCIDP

Expiration Date: 6-27-2020. The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. BCIDP accreditation begins 06/27/2019 for this activity and is available for one year from this date.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Jeffres has no relevant commercial or financial relationships to disclose.

Funding

This activity is provided by ProCE, Inc. and SIDP.

    

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.